Comparing two ways to manage relapsing-remitting MS
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests if it's safe to stop or reduce anti-CD20 treatment after several years of stable disease, compared to continuing it. It's for people with relapsing-remitting MS who are at least 40 years old and have had no MS activity for the past 3 years on anti-CD20 therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years or older
- You have relapsing-remitting multiple sclerosis
- You have been treated with anti-CD20 medication for at least 3 years
- You have had no MS relapses or new MRI lesions in the last 3 years
- You have had a brain MRI within the past 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether older adults (55+) with stable relapsing-remitting multiple sclerosis can safely stop their moderate-efficacy disease-modifying therapy. It aims to see if continuing treatment is still needed when the disease has been inactive for at least 5 years.
This study tests a new oral medication called Rocbrutinib for people with relapsing-remitting multiple sclerosis (RRMS). The drug targets a protein that may help reduce the immune system's attack on the brain and spinal cord. The trial will check if the medication can reduce new brain lesions and slow down disability progression.
This trial tests a new medicine called BCD-281 for people with relapsing-remitting multiple sclerosis (RRMS). It aims to see if the drug can reduce relapses and improve disease control.
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
This study looks at whether people with early relapsing multiple sclerosis can safely stop ocrelizumab. Researchers will compare health and MRI findings over time to see if stopping helps or increases relapse risk.
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
Hear when a new Relapsing-Remitting Multiple Sclerosis (RRMS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.